BioSpace News Archive

Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2021.

Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 2:00 p.m. ET.

Oculis S.A., (Oculis) a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, today announces that the first patients have been dosed in its Phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME) (DIAMOND – DIAbetic Macular edema patients ON a Drop).

Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced new details about its upcoming late breaker oral presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting, being held virtually from Nov. 12-15, 2021.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported financial results for the third quarter of 2021.

Sagimet Biosciences, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will give an oral presentation on consolidated results from the Phase 2 FASCINATE-1 trial of Sagimet’s lead clinical candidate TVB-2640 in patients in the U.S. and China with nonalcoholic steatohepatitis (NASH) on November 14 at The Liver Meeting 2021.

Epizyme, Inc. today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcare Conference.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights.

Amneal Pharmaceuticals, Inc. announced that its investor relations or management team will virtually attend the following investor conferences.

Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing.